Provider review
SurpassMD review
Answers its own asterisk instead of leaving it dangling.
Reviewed by Lena OrtizMetabolic Health Editor
Price updated August 2026
We may earn a commission at no extra cost to you. Affiliate partners are listed first on our rankings. How we’re funded.
$114/mo semaglutide and $177/mo tirzepatide, promotional
Visit SurpassMDThe advertised figures are promotional and conditional, and the FAQ says so.
Price as published
SurpassMD
$114/mo semaglutide and $177/mo tirzepatide, promotional
- Vs median
- $61/mo below the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Compounded, a 503A pharmacy, not named
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
In one paragraph
The verdict
The best thing here is that the asterisk gets answered. Two figures are advertised, both marked with one, and the FAQ then states plainly that they are promotional rates for eligible patients and that actual pricing depends on the medication. Most sellers in this category print the asterisk and leave it there, so you are left holding a qualified number with the qualification missing. Here the qualification is published, which means the advertised figures can be read for what they are: the best case rather than the case. That is a small piece of honesty that changes how much weight the numbers deserve. The oddity is the unit. Both figures are written per m rather than per month, consistently across the site, and in a category where four-week billing is common enough to have caught several other providers, an abbreviated unit is worth confirming rather than assuming. Cancellation terms are stated repeatedly and the pharmacy class is referenced. No milligram appears against either figure.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
Who it suits, and who it does not
A good fit if
- You want a seller that explains its own asterisk
- You want cancellation terms stated repeatedly rather than once
- You will confirm what the abbreviated unit means before ordering
Look elsewhere if
- You want a standing rate rather than a promotional one
- You want the billing period spelled out
- You want a dose behind the number
What it actually costs
Price as published
$114/mo semaglutide and $177/mo tirzepatide, promotional
- Vs median
- $61/mo below the $175 median across the 299 of 548 programs here that publish a plain monthly rate
- Market
- $59–$1,300/mo is the full published spread on this site
- Structure
- Standard plan, self-directed low dose
No low-dose product of its own. Starting low means asking for a smaller amount inside a standard plan, at the standard plan's price.
235 of the 548 programs here price a small dose this way. The asterisk gets answered, which is rare: the FAQ states the advertised figures are promotional, conditional on eligibility, and that actual pricing depends on the medication. A qualified number with its qualification published can at least be read for what it is. The billing unit is abbreviated throughout, which is worth confirming in a category where four-week billing has caught out buyers at several sellers here.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
What is included
- Consult
- Included in the price
- Dietitian
- Not confirmed
- Labs
- Not required
- Pricing
- Check plan terms
What it does well
- Resolves its own asterisk in the FAQ rather than leaving it dangling.
- States that actual pricing depends on the medication rather than implying the figure is fixed.
- Cancellation terms stated repeatedly, with the pharmacy class referenced.
Pharmacy, labs and oversight
SurpassMD says it uses a 503A pharmacy, but does not say which one. No bloodwork is required before you start. A clinician review is included in the price.
Transparency check
2 of 4 published openly
What SurpassMD publishes about itself, read from its own pages when we verified them — not estimated, and not a score.
- Pharmacy named and regulatedSays it uses a 503A pharmacy, but does not say which one.
- Not published
- A price you can read before intakeA monthly rate is published on its own pages — the figure in the price row above, read there and verified against it.
- Published
- What a higher dose costsPriced by dose, plan or tier, and the higher rungs are not published — the advertised figure does not tell you what a larger dose costs.
- Not published
- No FDA warning letter on fileChecked against the FDA's own warning-letter database; nothing on file for this company.
- None on file
How the program works
The best thing here is that the asterisk gets answered. Two figures are advertised, both marked, and the FAQ then states plainly that they are promotional rates for eligible patients and that actual pricing depends on the medication. Most sellers print the asterisk and leave it, so a reader is left holding a qualified number with the qualification missing. Here the qualification is published, which means the advertised figures can be read for what they are: the best case, not the case. The oddity is the unit. Both figures are written per m rather than per month, consistently, and in a category where four-week billing is common enough to have caught several rows on this page, an abbreviated unit is worth confirming rather than assuming. Cancellation terms are stated repeatedly and the pharmacy class is referenced. No milligram appears against either figure.
The honest cons
Both advertised figures are promotional and conditional on eligibility.
- The unit is abbreviated to per m throughout, which is ambiguous in this category.
- No milligram appears against either figure.
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
How it compares
SurpassMD is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.
Also consider
Two more programs that price a small dose the way SurpassMD does. Both are partners: we may earn a commission if you start care through these links.
Partner
Bodybuilding Health+
$179/mo sema · $209/mo tirz
Standard plan, self-directed low dose
Partner
Direct Meds
From $249/mo sublingual · $297/mo injection
Standard plan, self-directed low dose
FDA warning letter · Direct Meds · September 2025 · addressed to directmeds.com, Inc. dba DirectMeds. Details in our review.
Where this sits
#356 of 548
Ordered with the companies that pay us first, and SurpassMD is not one of them. A disclosed partition, not a score.
Compare all 548 providers →Read this before you buy
Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.
- What microdosing GLP-1 costs
- Low dose vs full dose
- The true annual cost of a plan
- What a flat price costs at a low dose
Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.
The closest alternative
RxSpan MD
$249/mo month to month ($199 on 6-mo)
- Vs median
- $74/mo above the $175 median
- Market
- $59–$1,300/mo across 299 of 548
- Structure
- Standard plan, self-directed low dose
- Dispensed
- Compounded by Belmar · Strive · Epiq Scripts · Casa Pharma Rx
Advertising disclosure · we may earn a commission if you start care through some of these links, at no extra cost to you.
Read the RxSpan MD review →Microdosing is off-label and unproven — decide with a clinician. Prices are as published by the provider when we last checked; confirm current terms before you buy.